Complete Story


Pfizer is Now Testing a COVID-19 Pill

The treatment is a potent protease inhibitor

Pharmaceutical giant Pfizer has kicked off early stage clinical trials of an experimental oral antiviral drug to treat COVID-19. 

The company announced on Tuesday the phase one trial of the drug, PF-07321332, is currently taking place in the U.S. 

The treatment is a potent protease inhibitor, the same kind of technology used to treat HIV and hepatitis C. Protease inhibitors bind to a viral enzyme and prevent the virus from replicating in the cell.

Please select this link to read the complete article from The Hill.

Printer-Friendly Version